About Us

Leadership

Leadership

An outstanding team committed to Helsinn's core values

Our Board of Directors and Leadership Team is composed of highly accomplished individuals from the pharma and biotech sectors. With the shared mission of supporting patients with cancer and chronic disease worldwide, the team at Helsinn aims to stay at the frontline of supportive care in cancer and chronic disease.

  • Filter
Executive Chairman & CEO
  • Appointed Executive Chairman and CEO in 2026.
  • Group Vice-Chairman and Board Member of 3B Future Holding SA, Switzerland (formerly Helsinn Holding Group).
  • Chairman, Chief Executive Officer and Managing Partner of the 3B Future Health Ventures S.a.r.l., Monaco, and Chairman and General Partner of 3B Future Health Fund I and II, Luxembourg.
  • Board Member of HAS Healthcare Advanced Synthesis, Switzerland.
  • Chairman of Nuovo Fiore in Africa Foundation, Switzerland.
  • Board Member of Medacta International, Switzerland, and of Thorne Holding Corporation, USA and Co-Founder and Board Member of Lyfebulb, USA.
  • Member of the Advisory Board of the New York City-based venture capital firm Windham Ventures, USA.
  • Member of the Board of the Conquer Cancer Foundation, USA, and Member of the CEO Roundtable on Cancer, USA, as well as of the Swiss-American Chamber of Commerce.
  • Holds a degree in Business Economics with a specialisation in Business Industrial Management from Bocconi University, Milan, Italy.

 

Chief Business Officer and Deputy CEO
  • Appointed Chief Business Officer and Deputy CEO in 2026.
  • Board Member of Helsinn since 2022.
  • 3+ years of experience in healthcare and pharmaceutical consulting.
  • Holds an MSc degree in Healthcare Management from City, University of London and a Bachelor’s degree in Business Management from Hult International Business School, London.

 

Board Member
  • Board Member of Helsinn since 2015.
  • Extensive legal experience, including roles at PriceWaterhouseCooper (PwC) and various positions at Bär & Karrer, including his current role as Resident Managing Partner.
  • Swiss Certified Tax Expert.
  • Holds a Master’s degree in Law from the University of Bern.

 

Board Member
  • Board Member of Helsinn since 2020.
  • Extensive experience in the pharmaceutical industry, having held various senior positions at Novartis and at the European Federation of Pharmaceutical Industries and Associations (EFPIA).
  • Previously Chairman of the Board at Novartis Japan.
  • Received the National Order of Merit in France in 2008.
  • Holds a Doctorate in Law from the University of Basel and a Master in Law from the University of California, Berkeley.
Board Member
  • Board Member of Helsinn since 2024.
  • Extensive experience in the pharmaceutical industry in both B2B and B2C international environments, including his current role as CEO of NTC S.r.l.
  • Holds a degree in Economics at Bocconi University in Milan.
Chief Financial Officer
  • Appointed Group Chief Financial Officer in 2013.
  • Held the role of Finance Director at Helsinn Birex Pharmaceuticals for more than 10 years.
  • +20 years of experience in senior financial positions in the pharmaceutical and electronics industries.
  • Extensive experience in greenfield start-up operations and corporate restructuring.
  • Prior to Helsinn, served as Financial Controller at Tyco Electronics and at Mallinckrodt Medical in a greenfield start-up operation.
  • Member of CIMA – Chartered Global Management Accountant.
  • Holds an International Executive Masters in Business Administration from Smurfit Graduate School of Business, Dublin, Ireland.

 

Chief Operating Officer
  • Appointed Chief Operating Officer in 2026.
  • Joined Helsinn in 2000 as Corporate Quality Assurance Manager and assumed responsibility for the CMC group in 2005.
  • 30+ years of experience in pharmaceutical industry in CMC, pharmaceutical development, supply chain and quality assurance.
  • Past experience as Responsible of Pharmaceutical Development department at Schering AG, Milan, Italy and Responsible of Quality Assurance at IBSA, Lugano, Switzerland.
  • Holds a PharmD in Chemistry and Pharmaceutical Technology from the University of Milan, Italy.

 

Chief Commercial Officer
  • Appointed Chief Commercial Officer in 2026.
  • 15+ years at Helsinn in a number of sales and licensing roles.
  • 25+ years of experience in the pharmaceutical industry with a focus on sales, marketing and out-licensing.
  • Prior to Helsinn, held sales and marketing roles at Baxter Healthcare Corporation, Alfa Sigma Corporation and GSK.
  • Holds an MBA from Bocconi University, Milan and a PhD in Molecular Biology from Dibit/HSR Milan and the Department of Genetics at Cambridge.
Chief of Staff
  • Appointed Chief of Staff in 2026.
  • 14+ years at Helsinn in a number of roles with increasing responsibility from cross-functional R&D project management in oncology, cancer supportive care and rare diseases to Group Senior Management.
  • 20+ years of R&D experience from academia to late-stage drug.
  • Past experience in preclinical development and project management at BioXell S.p.A., Italy, working in inflammation, urology and cancer.
  • Conducted basic research on cancer genetics at the University of Milan-Bicocca.
  • Holds a Master in Industrial Biotechnology, cum laude, from the University of Milan-Bicocca.

 

Group Head of Human Resources and Compliance
  • Joined Helsinn as Group Head of Human Resources and Compliance in 2025.
  • Over 30 years of experience in the pharmaceutical, biotech and FMCG industries, with a strong focus on human resources strategy, talent development and organizational transformation.
  • Past experience includes:
    • Vice President, Culture & People Western Europe and Germany at Stada
    • Global Head HR Manufacturing at Lonza Biotech
    • Global Head HR TechOps & Quality at Sandoz
    • Regional and global HR leadership positions at Novartis Vaccines & Diagnostics.
  • Holds a Bachelor of Arts in Spanish and French Literature and in Philosophy.
Linkedin X-twitter Vimeo

Helsinn Healthcare SA. All rights reserved. Helsinn Group 2025 ©

Exiting the US site

You are about to enter a website not intended for a US audience.
Please confirm your acceptance to continue

Continue
Cancel

Entering the US site

You are about to enter a website only intended for a US audience.
Please confirm your acceptance to continue.

Continue
Cancel

You are now leaving helsinn.com

Please click ‘Continue to external site’ if you want to continue.